Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, will be participating at tomorrow’s Emerging Growth Conference. The company announced that CEO Jim Joyce will give a live presentation; the presentation is slated to begin at 12 p.m. ET. According to the announcement, Joyce will provide an update on Sigyn Therapy(TM), the company’s novel blood-purification technology designed to address life-threatening conditions that are beyond the reach of drugs, and will review the company’s candidate products designed to enhance the benefit of chemotherapy and immunotherapeutic antibodies to treat cancer. The presentation will also include time for a Q&A. An archived copy of the webcast will be available following the presentation on the Emerging Growth YouTube channel.
To view the presentation, visit https://ibn.fm/9NH0s
To view the full press release, visit https://ibn.fm/DheyN
About Sigyn Therapeutics Inc.
Sigyn Therapeutics is a development-stage, medical-technology company headquartered in San Diego, California. The company’s therapeutic candidates are designed to overcome clearly defined limitations in healthcare. These include the ImmunePrepplatform, ChemoPrep, ChemoPure and Sigyn Therapy. ImmunePrep is a development-stage commercialization platform to enhance and extend the performance of immunotherapeutic antibodies, which account for 9 of the top 15 best-selling cancer therapy drugs. ChemoPrep is designed to optimize the delivery of chemotherapy, the most commonly administered drug to treat cancer, while ChemoPureextracts off-target chemotherapy from the bloodstream to reduce treatment toxicity. Sigyn Therapy is a novel blood-purification technology being advanced to treat pathogen-associated inflammatory disorders. In vitro studies have demonstrated the ability of Sigyn Therapyto reduce the circulating prevalence of 12 pathogen and inflammatory-disease targets from human blood plasma. Based on these outcomes, candidate treatment indications include community-acquired pneumonia, endotoxemia, drug-resistant viral and bacterial infections, endotoxemia and sepsis, the leading cause of hospital deaths in the United States. First-in-human feasibility studies of Sigyn Therapy plan to enroll end-stage renal disease (“ESRD”) patients with endotoxemia and concurrent inflammation, which are highly prevalent and associated with increased mortality in the ESRD population. For more information, visit the company’s website at www.SigynTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://ibn.fm/SIGY
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
